Skip to content

AuraGain Performance in Lateral Position

A Randomized Comparison of Pediatric® AuraGain in Supine, Moderate Lateral, and Extreme Lateral Positions in Terms of Clinical Performance and Fiber Optic Glottic

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05106478
Acronym
AuraGainLMA
Enrollment
52
Registered
2021-11-03
Start date
2021-11-01
Completion date
2023-12-29
Last updated
2024-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Complication of Anesthesia

Brief summary

To compare the clinical performance of AuraGain including insertion time and success rate at first attempt, fiberoptic bronchoscopic view, oropharyngeal leak pressure, the degree of ease of gastric tube insertion, and peri-operative adverse effects in young children in supine, moderate lateral and extreme lateral position.

Detailed description

Ambu® AuraGain, a relatively novel supraglottic airway device, has been introduced recently. AuraGain has an inflatable cuff and a curved body. In addition, because the airway tube of AuraGain is wide, it can be used as a conduit for tracheal intubation. However, only a limited number of studies have been conducted on the performance of AuraGain in pediatric patients. Changes in the position of the head and neck alter the shape of the pharynx leading to changes in the oropharyngeal leak pressure and the quality of ventilation through the LMA in both the adult and pediatric population. Having a large occiput and a relatively cephalically placed glottis, the ventilation in children is more compromised due to poor alignment of the pharyngeal-laryngeal axes during flexion of the head and neck. The hanging epiglottis covers the laryngeal inlet during flexion and the cuff of the LMA compresses the narrow laryngeal inlet both decreasing the delivered tidal volume. Different changes occur during extension and lateral rotation Although the clinical performance of the AuraGain would be expected to be high, or at least non-inferior, to that of the widely used currently available SGAs, clinical trials are required to verify its performance in head and neck positions other than the neutral position (i.e flexion, extension and lateral rotation).

Interventions

DEVICEAuraGain

Ambu® AuraGain, a relatively novel supraglottic airway device, has been introduced recently. AuraGain has an inflatable cuff and a curved body.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 9 Years
Healthy volunteers
No

Inclusion criteria

* Weight: 15-30 kg. * Age: 2-9 years. * Sex: both males and females. * ASA physical status: 1-3. * Operation: elective outpatient surgery in which airway management with a® AuraGain would be appropriate.

Exclusion criteria

* Active respiratory illness (cough, fever, rhinorrhea) on the day of anesthesia, * Potentially difficult airway. * Patients with history of neck, respiratory, or digestive tract pathology. * Patients with gastroesophageal reflux, gastrointestinal stenosis, or stricture.

Design outcomes

Primary

MeasureTime frameDescription
Oropharyngeal leak pressureIntraoperative from 1 minute after insertion of the device as a baseline to 60 minutes after insertion of the deviceAirway leak pressure will be determined by closing the adjustable expiratory pressure-limiting (APL) valve and setting the fresh gas flow rate to 3 L/min. The airway pressure at which an audible leak in the mouth is heard is recorded as the leak Pressure.

Secondary

MeasureTime frameDescription
Ventilation score (grade 0, 1, 2 or 3),Intraoperative from 1 minute after insertion of the device as baseline to 60 minutes after insertion of the devicethe ventilation score which is scored from 0 to 3 based on three criteria: no leakage with an airway pressure of 15 cm H2O, bilateral chest excursions with a peak inspiratory pressure of 20 cm of H2O, and a square wave capnogram, with each item scoring 0 or 1 point . Thus, if all three criteria are satisfied, the ventilation score is 3.
Fiberoptic glottic view ScoreIntraoperative from 1 minute after insertion of the device to 60 minutes after insertion of the device.The fiberoptic images will be graded with a score from 1 to 5, which has been defined and proposed previously (20, 21); (grade 1-only larynx seen; grade 2-larynx and epiglottis posterior surface seen; grade 3-larynx and epiglottis tip of anterior surface seen, \<50%visual obstruction of epiglottis to larynx; grade 4-epiglottis down folded and its anterior surface seen, \>50%visual obstruction of epiglottis to larynx; and grade 5-epiglottis down folded and larynx cannot be seen directly). The images will be taken in the neutral position and in mid and extreme laterally rotated neck positions.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026